Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing 100053, China.
Chin Med J (Engl). 2018 Jan 20;131(2):137-143. doi: 10.4103/0366-6999.222343.
Early neurological deterioration (END) is a prominent issue after recanalization treatment. However, few studies have reported the characteristics of END after endovascular treatment (EVT) as so far. This study investigated the incidence, composition, and outcomes of END after intravenous recombinant tissue plasminogen activator (IV rt-PA) and EVT of acute ischemic stroke, and identified risk factors for END.
Medical records of patients who received recanalization treatment between January 1, 2014, and December 31, 2015 were reviewed. Patients were classified into IV rt-PA or EVT group according to the methods of recanalization treatment. The END was defined as an increase in the National Institutes of Health Stroke Scale (NIHSS) ≥4 or an increase in Ia of NIHSS ≥1 within 72 h after recanalization treatment. Clinical data were compared between the END and non-END subgroups within each recanalization group.
Of the 278 patients included in the study, the incidence of END was 34.2%. The incidence rates of END were 29.8% in the IV rt-PA group and 40.2% in the EVT group. Ischemia progression (68.4%) was the main contributor to END followed by vasogenic cerebral edema (21.1%) and symptomatic intracranial hemorrhage (10.5%). Multivariate logistic regression showed that admission systolic blood pressure (SBP) ≥160 mmHg (odds ratio [OR]: 2.312, 95% confidence interval [CI]: 1.105-4.837) and large artery occlusion after IV rt-PA (OR: 3.628, 95% CI: 1.482-8.881) independently predicted END after IV rt-PA; and admission SBP ≥140 mmHg (OR: 5.183, 95% CI: 1.967-13.661), partial recanalization (OR: 4.791, 95% CI: 1.749-13.121), and nonrecanalization (OR: 5.952, 95% CI: 1.841-19.243) independently predicted END after EVT. The mortality rate and grave outcome rate at discharge of all the END patients (26.3% and 55.8%) were higher than those of all the non-END patients (1.1% and 18.6%; P < 0.01).
END was not an uncommon event and associated with death and grave outcome at discharge. High admission SBP and unsatisfactory recanalization of occluded arteries might predict END.
血管再通治疗后早期神经功能恶化(END)是一个突出的问题。然而,迄今为止,很少有研究报道血管内治疗(EVT)后 END 的特征。本研究探讨了急性缺血性脑卒中患者静脉内重组组织型纤溶酶原激活剂(IV rt-PA)和 EVT 后 END 的发生率、构成和结局,并确定了 END 的危险因素。
回顾了 2014 年 1 月 1 日至 2015 年 12 月 31 日期间接受再通治疗的患者的病历。根据再通治疗方法将患者分为 IV rt-PA 或 EVT 组。END 定义为血管再通治疗后 72 小时内 NIHSS 增加≥4 分或 NIHSS Ia 增加≥1 分。在每个再通组内,比较 END 和非 END 亚组之间的临床数据。
本研究共纳入 278 例患者,END 的发生率为 34.2%。IV rt-PA 组 END 的发生率为 29.8%,EVT 组为 40.2%。进展性缺血(68.4%)是 END 的主要原因,其次是血管源性脑水肿(21.1%)和症状性颅内出血(10.5%)。多变量 logistic 回归显示,入院时收缩压(SBP)≥160mmHg(比值比[OR]:2.312,95%置信区间[CI]:1.105-4.837)和 IV rt-PA 后大血管闭塞(OR:3.628,95%CI:1.482-8.881)独立预测 IV rt-PA 后 END;入院时 SBP≥140mmHg(OR:5.183,95%CI:1.967-13.661)、部分再通(OR:4.791,95%CI:1.749-13.121)和未再通(OR:5.952,95%CI:1.841-19.243)独立预测 EVT 后 END。所有 END 患者的死亡率和出院时严重结局率(26.3%和 55.8%)均高于所有非 END 患者(1.1%和 18.6%;P<0.01)。
END 并不少见,与出院时的死亡和严重结局有关。入院时较高的 SBP 和闭塞动脉不理想的再通可能预测 END。